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INTRODUCTION
Vesicoureteral reflux (VUR), a common urologic diag­
nosis that affects approximately 1% of all children, may 
increase the risk of  pyelonephritis and renal scarring. 
Before the introduction of endoscopic injection therapy, the 
mainstay of surgical treatment for VUR was open ureteral 
reimplantation. The cure rate, depending on the procedure 
and the severity of  reflux, was 98.1% (95% confidence 
interval [CI], 95.1–99.1) [1]. Drawbacks of open surgery are 
the abdominal incision, required hospitalization, temporary 
indwelling of a urinary catheter, and possible damage to 
the trigone. Minimally invasive surgical techniques have 
overcome some of these limitations; however, postoperative 
complications such ureteral obstruction still occasionally 
occur. 
Since Matouschek first used polytetrafluoroethylene 
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(PFTE, Teflon) injection at the ureteral orifice to treat VUR 
[2], endoscopic injection treatment has been widely used 
by urologists. This approach corrects VUR by injecting a 
bulking agent to elevate and coapt the ureteral orifice and 
detrusor tunnel. Endoscopic injection treatment is minimally 
invasive, performed on an outpatient basis, and technically 
straightforward, with a relatively short learning curve and 
low complication rate. These advantages have led to its 
widespread use in last 2 decades.
Considerable progress has been made regarding the 
injection technique and materials used. Dextranomer/
hyaluronic acid (Dx/HA, Deflux, Salix Pharmaceuticals, 
NJ, USA) is currently the most widely used bulking agent 
approved by the U.S. Food and Drug Administration 
(FDA) and has shown an overall mean success rate of 83% 
[1]. However, the reporting of long­term success rates and 
delayed complications has resulted in a controversy over 
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the use of endoscopic injection treatment. In this review, we 
reviewed the injection materials, techniques, success rates, 
and recent issues for endoscopic injection treatment.
MATERIALS FOR ENDOSCOPIC INJECTION
1. PTFE (Teflon)
PTFE is a widely used biomaterial for medical applica­
tions such as vascular grafts and tissue replacement patches 
and was the first material investigated for endoscopic 
treatment of VUR [2,3]. Since the experience with PTFE 
exceeds 20 years, long­term results and durability of 
PTFE have been assessed [4­6]. A study evaluating PFTE 
in patients with a mean follow­up of 13.5 years reported 
the absence of  ref lux in 95% of  injected ureters on 
routine voiding cystourethrogram (VCUG) [4]. These data 
demonstrated long­term durability and efficacy, even in 
high­grade reflux (III–V), with a success rate of  68.4%. 
However, there is a concern that PFTE particles could mig­
rate to other organs such as the brain and lungs [7,8]. Des­
pite of the convincing long­term outcome with PTFE, the 
concerning information regarding the possibility of particle 
migration limited the use of PTFE and it has been nearly 
abandoned. 
2. Polydimethylsiloxane (Macroplastique)
To reduce migration of implant particles while main­
taining a durable implant, polydimethylsiloxane was 
developed as a sof t tissue bulking agent. This solid, 
elastomeric silicone was incorporated into a patented device 
called Macroplastique (Congentix Medical, Orangeburg, 
NY, USA). Polydimethylsiloxane has a mean maximum 
particle diameter of 209 μm and is highly viscous, requiring 
an administration device that can withstand high pressure 
[9]. In comparison with other bulking agents, the higher 
viscosity and its nonresorbable nature preventing shrinkage 
of the product increase its reliability. This bulking agent 
has been used in Europe and Canada with success rates 
similar to those of other bulking agents [10]. Although a 
recent prospective study reported that polydimethylsiloxane 
resulted in a better success rate than Dx/HA (90% vs. 
81%, p<0.05), most of previous studies did not reveal major 
differences in success rates between polydimethylsiloxane 
and other materials. Most polydimethylsiloxane particles 
have diameters greater than 100 μm; however, the presence 
of  particles with diameters less than 80 μm raises the 
possibility of long­distance migration [11,12]. These concerns 
about migration have prevented polydimethylsiloxane from 
gaining popularity in the United States and it has been 
displaced by Dx/HA.
3. Dx/HA (Deflux)
After the FDA approved Dx/HA for the treatment 
of  VUR in 2001, even urologists who had considerable 
experience with PTFE switched to using Dx/HA. There was 
a rapid increase in the use of endoscopic injection therapy, 
and some researchers recommended Dx/HA injection 
as the first­line treatment for VUR [13,14]. Dx/HA is a 
highly viscous gel consisting of Dx microspheres (80–250 
μm in diameter) in non–animal-stabilized HA, which acts 
primarily as a carrier to deliver the biocompatible Dx to the 
implantation site.
Success rates for Dx/HA injection vary widely depending 
mainly on the VUR grade, and the overall success rate 
reported is 77% [15]. Although sufficient data have been 
accumulated to understand short­term success, the long­term 
durability of Deflux is still a subject of  concern. Several 
groups have published long­term results after endoscopic 
injection [16­21]. The time of last follow­up VCUG varied 
from 1 to 12 years, and overall recurrence rate ranged from 
12% to 54%. However, regular follow­up VCUG is required 
prospectively to evaluate the long­term durability of Deflux, 
even after postoperative images confirm the success of the 
procedure; therefore, there has been a lack of comprehensive 
long­term data until now.
4. Polyacrylate Polyalcohol copolymer (Vantris)
Polyacrylate Polyalcohol copolymer (PPC) (Vantris, 
Promedon, Córdoba, Argentina), a new nonbiodegradable 
substance of synthetic origin belonging to the acrylic family, 
was first introduced in 2010 to treat VUR [22]. The average 
diameter of particles is 320 nm which can reduce the risk 
of  migration and nonbiodegradable nature leads to the 
formation of  a fibrotic capsule that can result in better 
stability and long­term durability in treating VUR. Several 
studies reported successful short­term outcomes (88.6%–93.8% 
of  resolution rate) with PPC, which are similar or even 
superior to Dx/HA [23­25]. However, ureteral obstruction was 
more commonly seen in PPC group within several months or 
even years after injection [24­26] and a recent animal study 
also revealed that PPC leaded severe fibrosis on injection 
site [27]. These results have raised a caution for ureteral 
obstruction after PPC injection and a long­term data should 
be followed.
ENDOSCOPIC INJECTION TECHNIQUES
Subureteric Teflon injection (STING) was introduced 
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by O'Donnell and Puri [3] in 1984 and has been used as 
a representative technique for endoscopic injection. The 
STING technique involves inserting the needle 2–3 mm 
below the ureteric orifice at the 6 o'clock position, advancing 
it for 4–5 mm into the submucosal plane, and creating a 
mound that elongates the intramural ureter. The STING 
technique was still used widely after the introduction of Dx/
HA for injection therapy. The initial study on this procedure 
with Dx/HA reported a success rate of 69% 12 months after 
the procedure [28]. Drawbacks of this technique were the 
relatively low success rate and concern regarding the caudal 
migration of material.
A study published in 2004 reported that the success rate 
of the hydrodistention implantation technique (HIT), which 
is a modification of STING, was higher than that of the 
original STING procedure (92% HIT vs. 79% STING, p<0.05) 
[29]. The HIT procedure therefore became the representative 
injection technique. Advantages of HIT include better visua­
lization of the distal ureteral lumen, which enables more 
accurate placement of the injector needle at the distal ureter 
and better visualization of the lumen configuration during 
the procedure. In addition, the HIT procedure results in 
better coaptation of the distal ureter, whereas the STING 
procedure involves only the ureteral orifice. A recent meta­
analysis showed that the overall resolution of VUR was 
significantly higher for patients who underwent HIT (82.5%) 
compared to those who underwent STING (71.4%) (pooled 
odds ratio [OR], 0.54; 95% CI, 0.42–0.69; p<0.0001) [30]. 
In recent years, the HIT procedure has been modified 
to include 2 tandem intraluminal ureteric tunnel injections 
(double HIT). With hydrodistention, injection of  the 
bulking agent creates a bulge, which initially coapts the 
detrusor tunnel, and a second implant within the most 
distal intramural tunnel leads to coaptation of the ureteric 
orifice [31]. Double HIT requires a higher injection volume 
and has a reported success rate of up to 93% [32,33]. Results 
of a recent survey showed that double HIT was the most 
commonly used technique for endoscopic correction of VUR 
by pediatric urologists in the United States [34]. In our 
experience, multiple punctures of the mucosa can sometimes 
cause leakage of the injected material. Therefore, an addi­
tional distal ureter injection could be beneficial in the event 
of insufficient coaptation of the ureteric orifice after the 
first HIT injection. 
FACTORS RELATED TO THE SUCCESS OF 
ENDOSCOPIC INJECTION 
The single most important factor affecting the success 
rate of  endoscopic injection is the preoperative grade of 
VUR. Although the success rate varied depending on the 
authors’ conflicts of interest, overall success rates with Dx/
HA reported in a systematic review were 89% (grade I), 83% 
(grade II), 71% (grade III), 59% (grade IV), and 62% (grade 
V) [15]. As previously mentioned, many studies reported an 
increased success rate by using the HIT modification (89% 
HIT vs. 71% STING) [29] with some exceptional studies 
reporting no significant difference in success rates between 
the 2 approaches [35].
Surgeon experience is another important factor for 
successful results [18,36]. Kirsch et al. [18] demonstrated that 
their success rate increased after first 20 cases with further 
improvement after the first 100 cases (success rate of 60% 
for first 20 cases vs. 80% for last 20 cases). Our data with 
382 injections between January 2008 and December 2013 
are consistent with these findings. Results of cumulative 
sum analysis revealed that this improvement tended to 
flatten and then decline after the initial 110 cases. The 
success rate improved gradually with high­grade VUR, 
whereas relatively few cases were required to reach a 
stable success rate for grade II VUR. The key technical 
points gained through experience appear to be the ability to 
clearly visualize the ureteral floor, which facilitates needle 
placement to the proper depth. In addition, acclimatization 
to the pressure and volume of injection material required to 
create the mound may improve outcomes.
Results of  multivariate logistic regression analysis 
indicate that creation of a mound that elevates and coapts 
the orifice is the most important factor determining the 
success of endoscopic injection [37,38]. However, the mound 
morphology and lack of hydrodistention in the ureter are 
somewhat subjective. An online survey asking pediatric 
urologists to predict whether the procedure was successful 
based on the appearance of  the mound just after the 
injection showed that the mound morphology was not a 
reliable predictor of outcome [39]. Nevertheless, the surgeon’s 
impression of  needle placement, the injected volume, 
development of the mound, and tactile sensation of tissue 
distention still provide important information about the 
success of the procedure.
Although there is increased awareness of  bladder 
and bowel dysfunction (BBD) in patients with VUR, the 
role of BBD in the success of injection therapy is unclear 
[37,38,40,41]. According to articles cited in the 2010 American 
Urological Association guideline on the management of 
primary VUR and its meta­analysis, in children with VUR 
treated with subureteral injection therapy, resolution rates 
at 3–12 months were 50% for those with BBD and 89% for 
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those without BBD [1]. More recent studies report higher 
success rates, suggesting that injection therapy should be 
considered for patients with BBD [42­44]. However, the effect 
of BBD on the outcome of injection therapy is difficult to 
determine because of the complex manifestations of BBD, 
which include overactive bladder, urge incontinence, voiding 
postponement, underactive bladder, dysfunctional voiding, 
and constipation.
APPLICATION FOR COMPLEX CASES
1. Paraureteral diverticulum
For a paraureteral diverticulum (PUD), ureteral reim­
plantation is generally performed because of the presumed 
underlying structural defect of the ureteral hiatus. However, 
Perez­Brayfield et al. [45] reported a success rate of 67% for 
endoscopic injection therapy in patients with PUD. In a 
subsequent study, they reported a success rate of 81% after a 
single injection. Their results suggested that a diverticulum 
diameter greater than 2.6 times that of  the ureteral 
diameter was a risk factor for treatment failure; however, 
their study was limited by the small number of cases [46]. A 
more recent study reported a 79% success rate for endoscopic 
injection in 28 renal units in patients with PUD and 
identified the following predictors of success: low PUD index, 
late onset of reflux on VCUG, and position of the ureteral 
orifice [47]. Based on these evidences, injection therapy could 
be considered as a treatment option in selected cases of PUD.
2. Ureteral duplication
Results of a meta­analysis of endoscopic injection the­
rapy showed that the success rate for VUR in patients with 
ureteral duplication (50%) was lower than that of patients 
with single systems (73%) regardless of  VUR grade [48]. 
However, several studies evaluating potential predictors 
of  success with injection therapy reported that ureteral 
duplication was not associated with treatment failure 
[37,49]. More recent studies have reported better success 
rates (68.4%–73%) after a single injection [50­52], with the 
possibility of additional injections if needed.
PREVENTION OF URINARY TRACT IN-
FECTIONS AND RENAL DAMAGE
It remains unclear whether surgical correction of VUR 
using an endoscopic approach will prevent further renal 
damage or urinary tract infections (UTIs). The incidence 
of febrile UTIs after injection therapy has been reported 
as 0.75% to 27% after successful treatment [41,48,53] (Table Ta
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1). In a retrospective matched cohort study, Elder et al. 
[54] reported that the average number of UTIs in patients 
receiving antibiotic prophylaxis (0.28) was significantly 
higher than that of  patients receiving injection therapy 
(0.08), and results of the regression analysis revealed a 383% 
higher incidence of UTIs in the antibiotic prophylaxis group. 
However, results of a randomized trial in Sweden (Swedish 
reflux trial) demonstrated that the rate of  febrile UTIs 
was lower with endoscopic treatment (23%) compared with 
surveillance (57%) in girls, but did not differ significantly 
between endoscopic treatment and antibiotic prophylaxis [55]. 
No benefit from treatment was observed in boys older than 
1 year with dilating VUR regarding prevention of febrile 
UTI.
The ability of injection therapy to protect against renal 
damage is still unknown. Few studies have evaluated the 
development of  new renal damage, which includes both 
renal deterioration and scarring, following treatment of 
reflux with endoscopic injection [17,56]. One study reported 
that postoperative deterioration of  renal function was 
developed in 7.5% of  renal units and 9.1% of  patients, 
respectively without newly developed renal scar after 
successful endoscopic injection [17]. The Swedish reflux trial 
compared the development of renal damage in children with 
dilating VUR who were randomized to different treatments 
[56]. The results showed that girls who received antimicrobial 
prophylaxis had the lowest incidence of renal scarring after 
2 years, but the development of new renal damage in the 
injection therapy group did not differ significantly from 
that of the antibiotic prophylaxis or surveillance groups.
CURRENT TREND AND DEBATES ON 
ENDOSCOPIC INJECTION
After the FDA approved the use of Dx/HA to treat VUR 
in 2001, Dx/HA use dramatically increased between 2002 
and 2006 [13,57], with some authors even recommending Dx/
HA injection as the optimal first­line treatment for VUR [58]. 
However, according to a recent analysis of Pediatric Health 
Information System data, the trend of increased Dx/HA use 
was not sustained through 2011 [59]. This may be attributed 
in part to a change in the algorithm for evaluating UTIs 
to a less stringent “top­down approach,” which resulted 
in a lower incidence of  low­grade VUR. In addition, a 
shift toward decreasing interventions for low­grade VUR 
could reduce the usage of  Dx/HA while the number of 
reimplantations for high­grade VUR remains unchanged. 
Evidence supporting a non­interventional approach may be 
the reason for fewer patients receiving injection therapy, 
with aggressive therapy reserved for select patients [60,61].
With the emergence of this trend toward less­invasive 
therapy, concerns regarding the long­term durability and 
complications of injection therapy have also emerged. The 
concerns of opponents to injection therapy are the decreased 
success rate during long­term follow­up and delayed­onset 
ureteral obstruction. For example, Lee et al. [21] reported 
26% recurrence of VUR after 1 year, even in patients who 
showed immediate resolution of VUR (overall recurrence 
was 46%). Similarly, the Swedish reflux trial reported a 
20% recurrence rate after 2 years with grade III VUR or 
higher. Although the reason for VUR recurrence is unclear, 
migration of the deposited material, which is accelerated by 
BBD, may play a role. 
In addition to late recurrence of  VUR, an increasing 
number of  early and delayed ureteral obstructions have 
been reported, although the incidence was still lower than 
the rate associated with open surgery [62­65]. Most cases of 
ureteral obstruction were resolved after temporary double­J 
stenting [65], but some required open ureteral reimplantation 
because of  inflammatory foreign body reaction [62,66]. 
Because delayed ureteral obstruction may occur as long as 
5 years after injection therapy, it can be missed, resulting 
in silent loss of renal function. In addition, the calcification 
of  injection material may be misdiagnosed as ureteral 
stones, because the density of Dx/HA implants on CT scans 
increases over time, appearing as progressive histopathologic 
changes [67,68]. 
Despite these limitations, injection therapy still has a role 
in treating VUR. Many families grow tired of the seemingly 
endless series of VCUGs while waiting for VUR resolution 
and fear the long­term effects of antibiotic therapy, even at 
low doses. In our institution, we usually consider injection 
therapy for patients with late detected VUR causing 
febrile UTI, older than 1 year, who have a lower chance 
of  spontaneous resolution. Children with megaureter or 
large PUD are excluded from injection therapy. In light of 
recent studies reporting the low effectiveness of antibiotic 
prophylaxis and concerns about antibiotic­resistant strains 
[69], we believe injection therapy still has an important role 
in VUR treatment. Future research regarding the long­term 
efficacy in preventing UTIs and renal damage is required 
to determine the role of endoscopic injection therapy in the 
treatment of VUR.
CONCLUSIONS
Although open surgery remains the gold standard for 
treating VUR, the use of endoscopic injection therapy has 
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grown considerably for the last decade with the advent 
of  Dx/HA copolymer. Despite the excellent short­term 
success rate following injection therapy, increasing reports 
of complications such as delayed ureteral obstruction and 
concerns about durability limit the use of injection therapy. 
In addition, a less stringent approach for evaluating UTIs 
that resulted in lower detection of  low­grade VUR may 
have contributed to the decrease in endoscopic injection 
treatments. Nevertheless, endoscopic injection treatment is 
a convenient method that can cure the condition through 
a single procedure without the need for major surgery. 
Considering recent disappointing reports regarding the 
efficacy of  antibiotic prophylaxis, a revised approach to 
the management of  VUR may be needed, with patients 
classified according to several factors in addition to reflux 
grade. A future randomized, prospective, long­term follow­up 
study is required to determine the optimal use of injection 
therapy for VUR.
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